Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
Fuji
Accenture
Chubb
Argus Health
US Department of Justice
Cipla
Healthtrust
Teva

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,999,379

« Back to Dashboard

Summary for Patent: 8,999,379
Title:Transparent transdermal nicotine delivery devices
Abstract: A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%.
Inventor(s): Gale; Robert M. (Los Altos, CA)
Assignee: ALZA Corporation (Vacaville, CA)
Application Number:14/192,811
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 8,999,379

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us NICODERM CQ nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020165-006 Aug 2, 1996 OTC Yes No ➤ Sign Up ➤ Sign Up A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION ➤ Sign Up
Sanofi Aventis Us NICODERM CQ nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020165-005 Aug 2, 1996 OTC Yes No ➤ Sign Up ➤ Sign Up A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION ➤ Sign Up
Sanofi Aventis Us NICODERM CQ nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020165-004 Aug 2, 1996 OTC Yes Yes ➤ Sign Up ➤ Sign Up A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,999,379

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,622,136 Transparent transdermal nicotine delivery devices ➤ Sign Up
9,205,059 Transparent transdermal nicotine delivery devices ➤ Sign Up
8,075,911 Transparent transdermal nicotine delivery devices ➤ Sign Up
8,663,680 Transparent transdermal nicotine delivery devices ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,999,379

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 9916214 ➤ Sign Up
Canada 2354621 ➤ Sign Up
China 1331586 ➤ Sign Up
China 101693023 ➤ Sign Up
Czech Republic 20012230 ➤ Sign Up
Czech Republic 302035 ➤ Sign Up
Germany 69941629 ➤ Sign Up
European Patent Office 1140039 ➤ Sign Up
Denmark 1140039 ➤ Sign Up
European Patent Office 2158903 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Queensland Health
Deloitte
Fuji
Farmers Insurance
Citi
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot